News
MESO
--
0.00%
--
Where Do Hedge Funds Stand On Mesoblast Limited (MESO)?
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Mesoblast Limited (NASDAQ:MESO) based on that data. […]
Insider Monkey · 19h ago
Analysts Just Made A Stunning Upgrade To Their Mesoblast Limited (ASX:MSB) Forecasts
Simply Wall St. · 1d ago
AnPac Bio-Medical, Cocrystal Pharma leads healthcare gainers; Hepion Pharmaceuticals, Medigus among major losers
Gainers: AnPac Bio-Medical Science (ANPC) +110%, Cocrystal Pharma (COCP) +56%, Renalytix AI (RNLX) +31%, Precigen (PGEN) +13%, Chiasma (CHMA) +11%.Losers: Hepion Pharmaceuticals (HEPA) -29%, Medigus (MDGS) -12%, Retractable Technologies (RVP) -10%, Mesoblast (MESO) -9%, Myomo (MYO) -9%.
Seekingalpha · 2d ago
Mid-Afternoon Market Update: Dow Drops Over 100 Points; Mesoblast Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.46% to 29,346.95 while the NASDAQ rose 0.14% to 11,920.95. The S&P also fell, dropping 0.20% to 3,574.82.
Benzinga · 11/20 19:32
Mid-Day Market Update: Nasdaq Edges Higher; Nano Dimension Shares Plunge
Midway through trading Friday, the Dow traded down 0.43% to 29,355.69 while the NASDAQ rose 0.14% to 11,921.21. The S&P also fell, dropping 0.24% to 3,573.32.
Benzinga · 11/20 17:37
Titan Pharmaceuticals, Idera Pharmaceuticals leads healthcare gainers; AVROBIO, Stealth BioTherapeutics among losers
Gainers: Titan Pharmaceuticals (TTNP) +31%, Idera Pharmaceuticals (IDRA) +27%, Mesoblast (MESO) +20%, 22nd Century Group (XXII) +14%, Genfit (GNFT) +13%.Losers: AVROBIO (AVRO) -14%, Stealth BioTherapeutics (MITO) -14%, Kazia Therapeutics (KZIA) -12%, Liminal BioSciences (LMNL) -9%, Burning Rock Biotech (BNR) -9%.
Seekingalpha · 11/20 15:52
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Zacks · 11/20 15:17
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 11/20 12:37
Mesoblast Jumps After Novartis Backs Stem Cell Therapy for Covid
Bloomberg · 11/20 12:03
Mesoblast inks deal with Novartis to develop COVID-19/ARDS stem cell therapy, shares +17%
Mesoblast (MESO) surges 17% after entering into an exclusive worldwide license and collaboration agreement with Novartis (NVS) for the development, manufacture and commercialization of Mesoblast’s remestemcel-L, with an initial focus to develop
Seekingalpha · 11/20 06:45
FEYE, PNNT, MESO and CELP among after-hours movers
Gainers: [[MESO]] +27.6%. [[FEYE]] +20.4%. [[NGVC]] +15.7%. [[SMTS]] +15.1%. [[CAL]] +8.6%.Losers: [[FTSI]] -18.5%. [[PNNT]] -10%. [[CELP]] -8.4%. [[DUO]] -6.3%. [[ASYS]] -6.3%.
Seekingalpha · 11/19 22:46
Mesoblast EPS beats by $0.22, misses on revenue
Mesoblast (MESO): FQ1 GAAP EPS of -$0.0421 beats by $0.22.Revenue of $1.31M (-92.3% Y/Y) misses by $39.21M.Press Release
Seekingalpha · 11/19 22:43
Mesoblast Q1 EPS $(0.04) Down From $(0.01) YoY, Sales $1.30M Down From $17.05M YoY
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share. This is a 320 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $1.30 million in sales this
Benzinga · 11/19 22:41
Mesoblast Enters Global Collaboration With Novartis For Development, Manufacture And Commercialization Of Remestemcel-L For $50M Upfront Payment From Novartis, Plus $505M In Potential Milestone Payments
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), today announced that it has entered into an exclusive worldwide license and collaboration agreement with Novartis for the
Benzinga · 11/19 22:16
Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-L
GlobeNewswire · 11/19 22:12
Mesoblast Q1 Sales $1.30M Down From $17.05M YoY
Mesoblast (NASDAQ:MESO) reported $1.30 million in sales this quarter. This is a 92.37 percent decrease over sales of $17.05 million the same period last year.
Benzinga · 11/19 21:55
Mesoblast Reports License, Collaboration Deal With Novartis, Co. Will Receive $50M In Proceeds
-Reuters
Reuters · 11/19 21:52
Mesoblast Corporate Update and Financial Results Webcast
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021). Conference Call Details  The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via https://webcast.boardroom.media/mesoblast-limited/20201119/NaN5fb59c68f297810019932232The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.comAbout Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @MesoblastRelease authorized by the Chief Executive.For further information, please contact:Media Julie Meldrum T: +61 3 9639 6036 E:julie.meldrum@mesoblast.comKristen Bothwell T: +1 917 613 5434 E:kbothwell@rubenstein.com    Investors Schond Greenway T: +212 880 2060 E: schond.greenway@mesoblast.comPaul Hughes    T: +61 3 9639 6036 E: paul.hughes@mesoblast.com
GlobeNewswire · 11/19 21:19
Late-stage study with Mesoblast's COVID-19 candidate to continue unchanged
Independent Safety Monitoring Committee has completed second interim analysis for Mesoblast's (MESO) remestemcel-L Phase 3 study, in patients with moderate to severe acute respiratory distress syndrome due to COVID-19 infection, and recommended that the study
Seekingalpha · 11/11 11:49
Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 Trial in COVID-19 ARDS
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection had received a recommendation to continue from the independent Data Safety Monitoring Board (DSMB) following completion of the trial’s second interim analysis. The analysis was performed on the trial’s first 135 patients, 45% of the total target of up to 300 randomized patients, with the DSMB recommending continuation after reviewing the trial’s primary endpoint, all-cause mortality within 30 days of randomization and all safety data. The key secondary endpoint is days alive off mechanical ventilatory support within 60 days of randomization. Mesoblast Chief Medical Officer Dr Fred Grossman said: “We are very pleased with the recommendation by the DSMB, as we seek to confirm whether remestemcel-L improves survival in ventilated COVID-19 patients with moderate to severe ARDS. Patients who have co-morbidities or are older are likely to continue to be at high risk of ARDS and death,1-3 even if COVID-19 vaccines become available. This is why having a potential treatment that reduces mortality in these patients is so important.”ARDS is the principal cause of death in COVID-19 infection and is thought to be due to a dysregulated immune response in the lungs to COVID-19. Deaths continue to increase in ventilator-dependent ARDS patients as COVID-19 cases continue to surge globally. Despite improved treatment and earlier intervention in hospitalized COVID-19 patients overall, the mortality rate in COVID-19 ARDS patients who are over 60 years old remains more than 60%.1 These patients appear to be particularly refractory to corticosteroids such as dexamethasone 4-5 and have not responded to single cytokine antagonists, anti-virals, or anti-malaria agents. The Phase 3 trial aims to confirm findings from a pilot study at New York’s Mt Sinai Hospital in March-April this year where nine of 12 ventilator-dependent patients (75%) were successfully discharged from hospital a median of 10 days after receiving two intravenous doses of remestemcel-L within five days. The ongoing Phase 3 trial, which is treating patients across more than 20 hospitals in the United States, uses the same dosing regimen.Mesoblast holds an Investigational New Drug (IND) submission for remestemcel-L in COVID-19 ARDS, with trial size, protocol design, and endpoints developed with input from the United States Food and Drug Administration. The third and final interim analysis, when 60% of the randomized target has completed 30 days of follow-up, will occur in the coming weeks.References 1. Mortality of COVID-19 Admitted Patients on Mechanical Ventilators. Epic Health Research Network. June 26, 2020 2. Harrison SL., et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLOS Medicine. September 10, 2020. https://doi.org/10.1371/journal.pmed.1003321 3. Sanyaolu A., et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020 Jun 25: 1-8. doi: 10.1007/s42399-020-00363-4 4. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. New England Journel of Medicine. July 17, 2020. DOI: 10.1056/NEJMoa2021436 5. Tomazini BM., et.al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19. JAMA 2020;324(13):1307-1316.About Remestemcel-L Mesoblast’s lead product candidate, remestemcel-L, is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is thought to have immunomodulatory properties to counteract the cytokine storms that are implicated in various inflammatory conditions by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @MesoblastForward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. The risks, uncertainties and other factors that may impact our forward-looking statements include, but are not limited to: the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. Unless required by law, we do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.Release authorized by the Chief Executive.For further information, please contact:Media Julie Meldrum T: +61 3 9639 6036 E:julie.meldrum@mesoblast.com Kristen Bothwell T: +1 917 613 5434 E:kbothwell@rubenstein.com Investors Schond Greenway T: +212 880 2060 E: schond.greenway@mesoblast.com Paul Hughes T: +61 3 9639 6036 E: paul.hughes@mesoblast.com
GlobeNewswire · 11/11 11:00
Webull provides a variety of real-time MESO stock news. You can receive the latest news about Mesoblast through multiple platforms. This information may help you make smarter investment decisions.
About MESO
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.
More